VolitionRX (NYSEAMERICAN:VNRX) Price Target Lowered to $1.00 at HC Wainwright

VolitionRX (NYSEAMERICAN:VNRX) had its target price cut by HC Wainwright from $1.50 to $1.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other research firms have also issued reports on VNRX. D. Boral Capital restated a “buy” rating and issued a $3.00 price target on shares of VolitionRX in a research report on Thursday, March 26th. Maxim Group downgraded VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $2.33.

VolitionRX Trading Down 14.3%

NYSEAMERICAN:VNRX opened at $0.17 on Thursday. The company has a 50-day moving average of $0.22 and a 200-day moving average of $0.33. The firm has a market cap of $27.18 million, a price-to-earnings ratio of -0.78 and a beta of 1.33. VolitionRX has a twelve month low of $0.17 and a twelve month high of $0.94.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.71 million. On average, research analysts forecast that VolitionRX will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of VolitionRX in the 4th quarter valued at approximately $28,000. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX in the 4th quarter valued at approximately $34,000. Citadel Advisors LLC boosted its stake in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the period. Finally, Armistice Capital LLC boosted its stake in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.